ITEM 5.02          DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
                   APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
                   OFFICERS


On March 23, 2021, DexCom, Inc. ("Dexcom") announced that Jereme Sylvain was
promoted to Chief Financial Officer, in addition to remaining as Chief
Accounting Officer, effective March 19, 2021 (the "Appointment Date"). Mr.
Sylvain will serve as Dexcom's principal financial officer and principal
accounting officer for purposes of the Exchange Act. Mr. Sylvain is not a party
to and does not have any direct or indirect material interest in any transaction
with Dexcom required to be disclosed under Item 404(a) of Regulation S-K.
Effective as of the Appointment Date, Dexcom's current Chief Financial Officer,
Quentin Blackford, has agreed to resign from this position, but will remain in
his role as Dexcom's Chief Operating Officer.
Mr. Sylvain, age 41, has served as Dexcom's Senior Vice President, Finance and
Chief Accounting Officer since March 2020, and joined Dexcom in September 2018
as its Vice President, Finance and Corporate Controller. Prior to joining
Dexcom, Mr. Sylvain held various positions at NuVasive, Inc., including Vice
President, Corporate Controller and Chief Accounting Officer from August 2016 to
September 2018 and Vice President, Corporate Controller from March 2014 to
August 2016. Prior to joining Nuvasive, Mr. Sylvain held the role of Senior
Director, Finance with Thermo Fisher Scientific, where he was responsible for
global accounting for the life sciences solutions group. Mr. Sylvain joined
Thermo Fisher Scientific in February 2014, following its acquisition of Life
Technologies Corporation. From July 2007 to February 2014, Mr. Sylvain held
multiple finance and accounting roles at Life Technologies and its predecessor,
Invitrogen Corporation. Prior to joining Invitrogen in July 2007, Mr. Sylvain
was part of the public accounting firm Ernst & Young LLP. Mr. Sylvain obtained
his Certified Public Accounting license after receiving a Bachelors of Science
degree in Finance from Arizona State University and a Masters of Science in
Accountancy from the University of Notre Dame.
In connection with this promotion, Mr. Sylvain will receive a raise, with an
annual base salary of $379,500.07 and annual bonus opportunity equal to 75% of
his base salary, which will be effective immediately. Mr. Sylvain also received
a total equity grant of 6,627 restricted stock units or $2,587,500 based on the
average closing price of Dexcom common stock for the 30-trading day period as of
five business days prior to the grant date (the "Equity Award"). The Equity
Award consists of 5,301 time-based restricted stock units ("RSUs") and 1,326
performance-based restricted stock units ("PSUs") respectively. The RSUs will
vest in three equal annual installments beginning on the first anniversary of
the grant date, subject to the terms and conditions of Dexcom's Amended and
Restated 2015 Equity Incentive Plan, including his continued employment by
Dexcom on each vesting date. The PSUs may only be earned and vest upon
achievement of both operational goals in 2021 and our 3-year relative total
shareholder return (TSR) performance versus the Nasdaq Composite Index, as well
as Mr. Sylvain's continued employment by Dexcom on their vesting date. Mr.
Sylvain remains eligible to participate in the employee benefit plans that
Dexcom offers its other employees.
Dexcom announced the promotion of Mr. Sylvain in a press release furnished as
Exhibit 99.01 to this report and is incorporated herein by this reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.


  Number        Description

   99.01          Press release dated March 2    3    , 2021.

    104         Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses